Liraglutide (LEADER trial), semaglutide (SUSTAIN-6), and dulaglutide (REWIND trial) demonstrated significant reductions in major adverse cardiovascular events, while others showed cardiovascular safety without superiority
The more recent REDUCE-IT trial (n = 8,179) found that 4 g/day of icosapent ethyl (a purified eicosapentaenoic acid ethyl ester) significantly reduced cardiovascular death (HR 0.75, 95% CI 0.680.83), myocardial infarction, and stroke in high-risk individuals with elevated triglycerides despite statin therapy
It is essential for individuals experiencing GERD symptoms while on semaglutide to work closely with their healthcare provider to develop a tailored plan that addresses their specific needs and concerns
However, lower production costs may help drive affordability
Any use constitutes self-experimentation with an uncharacterized human safety profile which patients deserve to know before pursuing it
Your skin glows naturally when this cycle is healthy
